SRR10842373
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.600
- G2M_CHECKPOINT+0.600
- MITOTIC_SPINDLE+0.500
- MYC_TARGETS_V1+0.500
- DNA_REPAIR+0.300
- MYC_TARGETS_V2+0.300
- SPERMATOGENESIS+0.300
- TGF_BETA_SIGNALING+0.300
- MTORC1_SIGNALING+0.200
- UNFOLDED_PROTEIN_RESPONSE+0.200
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- INTERFERON_GAMMA_RESPONSE-0.500
- ADIPOGENESIS-0.400
- ALLOGRAFT_REJECTION-0.400
- BILE_ACID_METABOLISM-0.400
- COAGULATION-0.400
- COMPLEMENT-0.400
- APICAL_SURFACE-0.300
- ESTROGEN_RESPONSE_EARLY-0.300
- FATTY_ACID_METABOLISM-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-50-6591-01A-11R-1755-07 | — | cohortMD1 | 0.890 |
| 2 | de19e3c1-3508-4c13-b2cf-7079ee934a55 | — | — | 0.880 |
| 3 | SRR934937 | — | — | 0.879 |
| 4 | TCGA-E9-A1N8-01A-11R-A144-07 | — | E | 0.873 |
| 5 | TCGA-AC-A2BK-01A-11R-A21T-07 | — | E | 0.869 |
| 6 | BS_1AYRM596 | medulloblastoma | — | 0.868 |
| 7 | TCGA-77-8139-01A-11R-2247-07 | — | cohortSQ1 | 0.865 |
| 8 | SRR8613800 | — | D | 0.859 |
| 9 | TCGA-A1-A0SK-01A-12R-A084-07 | — | E | 0.857 |
| 10 | 2bd9ef82-12dc-4dcb-8a2c-c58cdf463116 | — | — | 0.857 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.600 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.600 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |